Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,252 shares of Evolus stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $10.85, for a total transaction of $24,434.20. Following the sale, the insider now directly owns 366,595 shares in the company, valued at $3,977,555.75. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Evolus Stock Performance

Shares of NASDAQ EOLS traded up $0.50 during trading on Thursday, reaching $11.35. The stock had a trading volume of 541,978 shares, compared to its average volume of 588,928. The firm’s 50 day moving average price is $13.56 and its two-hundred day moving average price is $13.75. Evolus, Inc. has a one year low of $9.80 and a one year high of $17.82. The stock has a market cap of $718.69 million, a PE ratio of -12.47 and a beta of 1.27. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its stake in Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after acquiring an additional 265,635 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Evolus by 24.6% during the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after purchasing an additional 35,760 shares during the last quarter. Armistice Capital LLC acquired a new position in Evolus during the 2nd quarter valued at approximately $3,906,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Evolus during the 3rd quarter worth $940,000. Finally, Lord Abbett & CO. LLC increased its position in Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after buying an additional 188,685 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th. Barclays upped their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research note on Monday, September 16th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.